Use of Stem Cell Therapy in COVID-19

Özdemir, Öner; Özer Aslan, İlke; Aslan, Mustafa Törehan

doi:10.14744/scie.2022.26086

Use of Stem Cell Therapy in COVID-19

Mustafa Törehan ASLAN, (Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi, Pediatri Bölümü, Neonatoloji Anabilim Dalı, Tekirdağ, Türkiye)

Öner ÖZDEMİR, (Sakarya Üniversitesi Eğitim ve Araştırma Hastanesi, Pediatri Anabilim Dalı, Pediatrik Alerji ve İmmünoloji Anabilim Dalı, Sakarya, Türkiye)

İlke Özer ASLAN (Tekirdağ Namık Kemal Üniversitesi, Tıp Fakültesi, Kadın Hastalıkları, Doğum ve Jinekoloji Anabilim Dalı, Tekirdağ, Türkiye)

Southern Clinics of Istanbul Eurasia

0 0

Yıl: 2022 Cilt: 33 Sayı: 3 Sayfa Aralığı: 331 - 335 Metin Dili: İngilizce DOI: 10.14744/scie.2022.26086 İndeks Tarihi: 28-10-2022

Use of Stem Cell Therapy in COVID-19

Öz:

Severe acute respiratory syndrome coronavirus 2 is known to cause the new coronavirus disease 2019 (COVID-19), in which many organs and systems such as the lung, heart, and immune system can be severely affected. Currently, the treatment process is generally based on supportive and palliative care. Some potential drugs are being tested for treatment. At this point, perhaps a promising treatment method for many diseases in the future seems to be stem cell therapy in recent times. Stem cell therapy in COVID-19 may be a treatment method that can play an important role, especially in resistant and severe cases. In this review, we summarized the potential mechanisms of stem cell therapy and developments in this treat ment modality.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman AR, et al. Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol 2020;5:eabd7114.
2. Song JW, Zhang C, Fan X, Meng FP, Xu Z, Xia P, et al. Immunologi cal and inflammatory profiles in mild and severe cases of COVID-19. Nat Commun 2020;11:3410.
3. Metcalfe SM. Mesenchymal stem cells and management of COVID-19 pneumonia. Med Drug Discov 2020 5:100019.
4. Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, et al; Sinai Immunology Review Project. Immunology of COVID-19: Current state of the science. Immunity 2020;52:910–41.
5. Samsonraj RM, Raghunath M, Nurcombe V, Hui JH, van Wijnen AJ, Cool SM. Concise review: Multifaceted characterization of human mesenchymal stem cells for use in regenerative medicine. Stem Cells Transl Med 2017;6:2173–85.
6. Gorman E, Shankar-Hari M, Hopkins P, Tunnicliffe WS, Perkins GD, Silversides J, et al. Repair of acute respiratory distress syn drome by stromal cell administration in COVID-19 (REALIST COVID-19): a structured summary of a study protocol for a ran domised, controlled trial. Trials 2020;21:462.
7. Lee JW, Krasnodembskaya A, McKenna DH, Song Y, Abbott J, Matthay MA. Therapeutic effects of human mesenchymal stem cells in ex vivo human lungs injured with live bacteria. Am J Respir Crit Care Med 2013;187:751–60.
8. Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mes enchymal stem cells (UC-MSCs) as a therapeutic strategy in manag ing critically Ill COVID-19 patients: The case for compassionate use. Pain Physician 2020;23:E71–E83.
9. Pittenger MF, Discher DE, Péault BM, Phinney DG, Hare JM, Ca plan AI. Mesenchymal stem cell perspective: cell biology to clinical progress. NPJ Regen Med 2019;4:22.
10. Ullah M, Liu DD, Thakor AS. Mesenchymal stromal cell homing: mechanisms and strategies for improvement. iScience 2019;15:421– 38.
11. Fan E, Beitler JR, Brochard L, Calfee CS, Ferguson ND, Slutsky AS, et al. COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? Lancet Respir Med 2020;8:816–21.
12. Jung YJ, Park YY, Huh JW, Hong SB. The effect of human adipose derived stem cells on lipopolysaccharide-induced acute respiratory distress syndrome in mice. Ann Transl Med 2019;7:674.
13. El-Metwaly S, El-Metwaly S, El-Senduny FF, El-Demerdash RS, Abdel-Aziz AF. Mesenchymal stem cells alleviate hydrochloric acid induced lung injury through suppression of inflammation, oxidative stress and apoptosis in comparison to moxifloxacin and sildenafil. Heliyon 2019;5:e02710.
14. Arutyunyan I, Elchaninov A, Makarov A, Fatkhudinov T. Umbilical cord as prospective source for mesenchymal stem cell-based therapy. Stem Cells Int 2016;2016:6901286.
15. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gom mers DAMPJ, Kant KM, et al. Incidence of thrombotic complica tions in critically ill ICU patients with COVID-19. Thromb Res 2020;191:145–47.
16. Häberle H, Magunia H, Lang P, Gloeckner H, Körner A, Koeppen M, et al. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS. J Intensive Care Med 2021;36:681–8.
17. Centers for Disease Control and Prevention. Stem cell and exosome products. 2019. Available at: https://www.cdc.gov/hai/outbreaks/ stem-cell-products.html. Accessed Feb 12, 2021.
18. Lanzoni G, Linetsky E, Correa D, Messinger Cayetano S, Alvarez RA, Kouroupis D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med 2021;10:660–73.
19. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplan tation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 2020;11:216–28.
20. Liang B, Chen J, Li T, Wu H, Yang W, Li Y, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells: A case report. Medicine (Baltimore) 2020;99:e21429.
21. Zengin R, Beyaz O, Koc ES, Akinci IO, Kocagoz S, Sagcan G, et al. Mesenchymal stem cell treatment in a critically ill COVID-19 pa tient: a case report. Stem Cell Investig 2020;7:17.
22. Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, et al. Clinical study of mesenchymal stem cell treatment for acute respiratory distress syn drome induced by epidemic influenza a (H7N9) infection: A hint for COVID-19 treatment. Engineering (Beijing) 2020;6:1153–61.
23. Coppin L, Sokal E, Stéphenne X. thrombogenic risk induced by in travascular mesenchymal stem cell therapy: Current status and future perspectives. Cells 2019;8:1160.
24. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Sum mary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323:1239–42.
25. Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, et al, Chinese Pediatric Novel Coronavirus Study Team. SARS-CoV-2 infection in children. N Engl J Med 2020;382:1663–5.
26. CDC COVID-19 Response Team. Coronavirus disease 2019 in Children - United States, February 12-April 2, 2020. MMWR Morb Mortal Wkly Rep 2020;69:422–6.
27. WHO. Report of the WHO-China joint mission on coronavirus dis ease 2019 (COVID-19). Geneva: WHO; 2020.
28. Pierce-Williams RAM, Burd J, Felder L, Khoury R, Bernstein PS, Avila K, et al. Clinical course of severe and critical coronavirus disease 2019 in hospitalized pregnancies: a United States cohort study. Am J Obstet Gynecol MFM 2020;2:100134.
29. Rothan HA, Byrareddy SN. The epidemiology and pathogene sis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020;109:102433.
30. Sanie-Jahromi F, NejatyJahromy Y, Jahromi RR. A review on the role of stem cells against SARS-CoV-2 in children and pregnant women. Int J Mol Sci 2021;22:11787.
31. Samara A, Herlenius E. Is there an effect of fetal mesenchymal stem cells in the mother-fetus dyad in COVID-19 pregnancies and vertical transmission? Front Physiol 2021;11:624625.
32. Zhang Z, Guo L, Lu X, Zhang C, Huang L, Wang X, et al. Clin ical analysis and pluripotent stem cells-based model reveal possible impacts of ACE2 and lung progenitor cells on infants vulnerable to COVID-19. Theranostics 2021;11:2170–81.
33. Verdecchia P, Cavallini C, Spanevello A, Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur J Intern Med 2020;76:14–20.

APA	Aslan M, Özdemir Ö, Özer Aslan İ (2022). Use of Stem Cell Therapy in COVID-19. , 331 - 335. 10.14744/scie.2022.26086
Chicago	Aslan Mustafa Törehan,Özdemir Öner,Özer Aslan İlke Use of Stem Cell Therapy in COVID-19. (2022): 331 - 335. 10.14744/scie.2022.26086
MLA	Aslan Mustafa Törehan,Özdemir Öner,Özer Aslan İlke Use of Stem Cell Therapy in COVID-19. , 2022, ss.331 - 335. 10.14744/scie.2022.26086
AMA	Aslan M,Özdemir Ö,Özer Aslan İ Use of Stem Cell Therapy in COVID-19. . 2022; 331 - 335. 10.14744/scie.2022.26086
Vancouver	Aslan M,Özdemir Ö,Özer Aslan İ Use of Stem Cell Therapy in COVID-19. . 2022; 331 - 335. 10.14744/scie.2022.26086
IEEE	Aslan M,Özdemir Ö,Özer Aslan İ "Use of Stem Cell Therapy in COVID-19." , ss.331 - 335, 2022. 10.14744/scie.2022.26086
ISNAD	Aslan, Mustafa Törehan vd. "Use of Stem Cell Therapy in COVID-19". (2022), 331-335. https://doi.org/10.14744/scie.2022.26086

APA	Aslan M, Özdemir Ö, Özer Aslan İ (2022). Use of Stem Cell Therapy in COVID-19. Southern Clinics of Istanbul Eurasia, 33(3), 331 - 335. 10.14744/scie.2022.26086
Chicago	Aslan Mustafa Törehan,Özdemir Öner,Özer Aslan İlke Use of Stem Cell Therapy in COVID-19. Southern Clinics of Istanbul Eurasia 33, no.3 (2022): 331 - 335. 10.14744/scie.2022.26086
MLA	Aslan Mustafa Törehan,Özdemir Öner,Özer Aslan İlke Use of Stem Cell Therapy in COVID-19. Southern Clinics of Istanbul Eurasia, vol.33, no.3, 2022, ss.331 - 335. 10.14744/scie.2022.26086
AMA	Aslan M,Özdemir Ö,Özer Aslan İ Use of Stem Cell Therapy in COVID-19. Southern Clinics of Istanbul Eurasia. 2022; 33(3): 331 - 335. 10.14744/scie.2022.26086
Vancouver	Aslan M,Özdemir Ö,Özer Aslan İ Use of Stem Cell Therapy in COVID-19. Southern Clinics of Istanbul Eurasia. 2022; 33(3): 331 - 335. 10.14744/scie.2022.26086
IEEE	Aslan M,Özdemir Ö,Özer Aslan İ "Use of Stem Cell Therapy in COVID-19." Southern Clinics of Istanbul Eurasia, 33, ss.331 - 335, 2022. 10.14744/scie.2022.26086
ISNAD	Aslan, Mustafa Törehan vd. "Use of Stem Cell Therapy in COVID-19". Southern Clinics of Istanbul Eurasia 33/3 (2022), 331-335. https://doi.org/10.14744/scie.2022.26086